This company brings in 30-40 Million a year. I think the stock has been pushed down a little too far in light of the closing of the HemaBio segment. Now they can focus on what they do best. HemaBio was only bringing in $300,000 a Qt. It is a hard pill for them to swallow in the form of closing costs but, a needed one. Next Qt they can bring in the same 10 Million as always and shareholders should be happy again.